Clinical trial
SPAN: A Phase 2, Open Label, Multicenter, Pilot Study to Assess Safety and Efficacy of an Enteric Microgranule Formulation of Adrulipase in Patients With Exocrine Pancreatic Insufficiency (EPI) Due to Cystic Fibrosis (CF)
NCT05719311 is registered in ClinicalTrials.gov with Entero Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- SPAN: A Phase 2, Open Label, Multicenter, Pilot Study to Assess Safety and Efficacy of an Enteric Microgranule Formulation of Adrulipase in Patients With Exocrine Pancreatic Insufficiency (EPI) Due to Cystic Fibrosis (CF)
- Lead sponsor
- Entero Therapeutics
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- February 1, 2023
- Completion date
- July 28, 2023
- Enrollment
- 13 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.